Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    14770429 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: Sunitinib Malate (Sutent)

Indicates status has not been verified in more than two years